Roche's Phase III ATOMIC Study Drives FDA Priority Review For Tecentriq Plus Chemotherapy As Potential New Standard Of Care In Stage III dMMR/MSI-H Colon Cancer
Filing acceptance is based on the phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50% versus chemotherapy alone1
Nearly one in three patients with stage III colon cancer relapse within five years, highlighting a critical need for new adjuvant treatment options2,3
If approved, Tecentriq plus chemotherapy could provide a new standard of care for the treatment of stage III dMMR/MSI-H* colon cancer after surgery
Login to comment